Naomi Nakajima

  • Citations Per Year
Learn More
To identify factors affecting local control of stereotactic body radiotherapy (SBRT) for lung tumors including primary lung cancer and metastatic lung tumors. Between June 2006 and June 2009, 159 lung tumors in 144 patients (primary lung cancer, 128; metastatic lung tumor, 31) were treated with SBRT with 48–60 Gy (mean 50.1 Gy) in 4–5 fractions. Higher(More)
BACKGROUND To define the factors associated with increased risk of isolated locoregional failure that may justify postmastectomy radiotherapy in patients with T1/2 breast cancer and 1-3 positive lymph nodes. METHODS Between 1990 and 2002, 248 patients who had pT1-2 breast cancer and 1-3 positive lymph nodes were treated with mastectomy without(More)
PURPOSE To determine whether volume-based parameters on pretreatment (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer patients treated with mastectomy without adjuvant radiation therapy are predictive of recurrence. METHODS AND MATERIALS We retrospectively analyzed 93 patients with 1 to 3 positive axillary nodes(More)
OBJECTIVE Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. When mass-like consolidation is observed on follow-up CT after(More)
Follow-up by chest CT is often performed routinely after stereotactic body radiotherapy (SBRT) for primary lung cancer. We investigated how often periodical chest CT detected lung-cancer related chest events (failure in the chest, new primary lung cancer), and how often chest CT follow-ups led to curative intent salvage treatment. Between 2006 and 2009, 90(More)
BACKGROUND There is still controversy concerning the indication of postmastectomy radiotherapy (PMRT) for pT3N0M0 breast cancer. To identify the candidates for PMRT in this subset, we investigated failure patterns, and searched for risk factors for isolated locoregional failure in pT3N0M0 breast cancer after mastectomy without PMRT. METHODS Among 1,176(More)
BACKGROUND The impact of aggregate of risk factors on isolated locoregional failure after mastectomy without radiotherapy was assessed. METHODS We reviewed 1091 patients who had stage I-III unilateral breast cancer and received mastectomy between 1990 and 2002. RESULTS Median follow-up time was 67 (1-175) months. On multivariate analysis, four or more(More)
  • 1